Prof Eleni Efstathiou, MD, PhD
Oncology — The University of Texas MD Anderson Cancer Center, United States
Eleni Efstathiou
LeadR Profile
Oncology
Subspecialties: Urology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 325
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study. diabetes mellitus, mortality, stroke, gonadotropin-releasing hormone, neoplasms, cohort studies, prostate, hormones, prostatic neoplasms, therapeutics | Urol Oncol | 2026 | 0 |
| A multi-modal approach for decision making in bladder cancer. urinary bladder, urinary bladder neoplasms, cystoscopy, neoplasms, multiple chronic conditions, decision making, therapeutics, artificial intelligence | Nat Rev Urol | 2026 | 0 |
| Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. cells, neoplastic cells, circulating, biomedical research, neoplasms, prostate, biomarkers, prostatic neoplasms, castration, therapeutics, chromosomal instability | JCI Insight | 2025 | 0 |
| Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. genes, confidence intervals, poly(adp-ribose) polymerases, progression-free survival, prednisone, neoplasms, abiraterone acetate, prostate, acetates, poly adenosine diphosphate ribose, drug-related side effects and adverse reactions, recombinational dna repair, prostatic neoplasms, castration, therapeutics | Nat Med Top journal | 2025 | 0 |
| Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. genes, quality of life, urology, pain, neoplasms, prostate, recombinational dna repair, prostatic neoplasms, patient reported outcome measures, castration, therapeutics, genes, brca1 | Eur Urol | 2024 | 3 |
Clinical Studies 21
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin ineligible Muscle Invasive Bladder Cancer NCT05241340 — radiotherapy, urinary bladder, urinary bladder neoplasms, muscles, lymph nodes, vaccines, radiosurgery, antineoplastic agents, immunological, antineoplastic agents, neoplasms, urologic diseases, immunoglobulins, urinary diversion, urologic neoplasms, immunotherapy, cystectomy, immune checkpoint inhibitors, lymph, neoadjuvant therapy, antibodies, monoclonal, urinary bladder diseases, therapeutics, prostatectomy, dissection, carcinoma | Phase 2 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map